Materias dentro de su búsqueda.
Mostrando 2,961 - 2,980 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.74s Limitar resultados
  1. 2961
    por Ozcan, Gulnihal
    Publicado 2023
    “…INTRODUCTION: Endeavors in the molecular characterization of breast cancer opened the doors to endocrine therapies in ER+/HER2- breast cancer, increasing response rates substantially. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer
  2. 2962
    “…In the evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) — one of the standard biomarkers for breast cancer— visual assessment is laborious and subjective. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Standardizing HER2 immunohistochemistry assessment: calibration of color and intensity variation in whole slide imaging caused by staining and scanning
  3. 2963
    “…LIVE/DEAD Cell Imaging was to detect live and dead cells. HER3 recognition by our anti-HER3 monoclonal antibody (mAb) 4A7 was verified by ELISA, flow cytometry, and co-immunoprecipitation assays. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
  4. 2964
    “…BACKGROUND: Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express low levels of HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
  5. 2965
    “…METHODS: From November 2017 to April 2022, 102 and 34 patients with a diagnosis of HER2-negative AGC at the First Affiliated Hospital of Bengbu Medical College were enrolled as development and validation cohorts, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
  6. 2966
    “…We herein describe the outline of a prospective/retrospective study which aims to explore the optimal sequence of treatment in HER2+, pertuzumab pre-treated ABC patients treated in II line with anti-HER2 agents in clinical practice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
  7. 2967
    “…CuCo(2)S(4) as a spinel-structured transition metal sulfide is a highly effective HER catalyst due to its excellent endurance, low overpotential, and low Tafel slope. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effect of urea and ammonium fluoride ratio on CuCo(2)S(4)/NF as a highly efficient HER catalyst
  8. 2968
    “…To study the changes in human epidermal growth factor receptor 2 (HER2) expression in patients with HER2-positive breast cancer before and after neoadjuvant treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
  9. 2969
    “…BACKGROUND: HER2 immunohistochemistry (IHC) reproducibility is suboptimal for HER-low cases (IHC 1+ or 2+). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
  10. 2970
    “…BACKGROUND: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
  11. 2971
    “…CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
  12. 2972
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
  13. 2973
    “…BACKGROUND: The relative lack of specifically targeted agents for HER2-negative metastatic breast cancer (MBC) makes the need for new agents or combination therapies to maximize clinical benefit while reducing toxicity critical. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
  14. 2974
    por Ness, Tove Mentsen, Silan, Wasiq
    Publicado 2023
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “We Tried to Take Care of Her, but it Got Too Exhausting”: A Study of the Transition From Family Carer to Employer
  15. 2975
    “…This study aimed to elucidate the clinical characteristics, primary/metastatic lesion HER2 expression, and treatment outcomes of HoR-positive/HER2-low patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
  16. 2976
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A 10-year-old Girl with a Melon Seed-like Nail on her Index Finger: A Quiz
  17. 2977
    “…The optimal treatment sequence for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer remains unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
  18. 2978
    “…The targeted therapies tested were erlotinib (EGFR inhibitor), neratinib (EGFR/HER2/HER4 inhibitor) and tucatinib (HER2 inhibitor). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
  19. 2979
    “…INTRODUCTION: The prognostic significance of HER-2/neu in breast cancer is a matter of controversy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
  20. 2980
    “…BACKGROUND: The Affibody molecule, ABY-025, has demonstrated utility to detect human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium-111 ((111)In) or gallium-68 ((68)Ga). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [(68)Ga]Ga-ABY-025 tracer
Herramientas de búsqueda: RSS